Results 101 to 110 of about 24,787 (310)

Dupilumab – a novel treatment option against allergic diseases: a state-of-the-art review

Alergologia Polska
Dupilumab is a humanized, IgG4 monoclonal antibody which binds to the α subunit of interleukin 4 receptor (IL-4R) and interleukin 13 receptor (IL-13R), thereby it inhibits their action.
Klaudia Kołakowska, Maciej Czubek
doaj   +1 more source

Inhalation therapy in the next decade : Determinants of adherence to treatment in asthma and COPD [PDF]

, 2018
Peer reviewedPublisher ...
Amaducci, Sandro, Bacci, Elena, Baldacci, Sandra, Bartoli, Maria L., Beghi, Gianfranco M., Benfante, Alida, Brighindi, Sara, Casali, Lucio, Castiglia, Daniela, Cazzola, Mario, Celi, Alessandro, Cianchetti, Silvana, Colombo, Giorgio, Crimi, Claudia, d'Alcontres, Martina Stagno, Dente, Federico L., Di Maria, Annalisa, Di Maria, Giuseppe, Donner, Claudio F., Hui Xin, Shaylynn Yu, Latorre, Manuela, Lavorini, Federico, Maio, Sara, Mannini, Claudia, Messina, Riccardo, Paggiaro, Pier Luigi, Pignatti, Patrizia, Pistolesi, Massimo, Price, David, Scichilone, Nicola, Simoni, Marzia, Spanevello, Antonio, Tan, Shwana, Torchio, Roberto, Viegi, Giovanni, Visca, Dina, Wouters, Emiel F.M.   +36 more
core   +5 more sources

Unique Features of Nasal Airway and Airflow Improvement Post‐Dupilumab: A Computational Cohort Study

The Laryngoscope, EarlyView.
The impact of dupilumab on nasal airway patency and airflow is not uniform. It is more pronounced in the middle and superior, but not inferior meatus. These unique regional changes significantly correlate with and potentially drive the improvement in patient symptoms.
Ahmad Odeh, Zhenxing Wu, Nidhi Jha, Aspen R. Schneller, James Mihalich, Zachary T. Root, Christopher Brooks, Casey Curtis, Monica Kraft, Kara Wada, Bradley A. Otto, Kathleen M. Kelly, Kai Zhao   +12 more
wiley   +1 more source

Dupilumab Reduces Urticaria Activity, Itch, and Hives in Patients with Chronic Spontaneous Urticaria Regardless of Baseline Serum Immunoglobulin E Levels

Dermatology and Therapy
Introduction In chronic spontaneous urticaria (CSU), interleukin (IL)-4 and IL-13 may promote mast cell activation directly via IL-4 receptor expression, or indirectly via upregulated immunoglobulin E (IgE) production.
Marcus Maurer, Thomas B. Casale, Sarbjit S. Saini, Moshe Ben-Shoshan, Elizabeth Laws, Jennifer Maloney, Deborah Bauer, Allen Radin, Melanie Makhija   +8 more
doaj   +1 more source

Long-term mortality outcomes among immunotherapy recipients treated with dupilumab for the management of cutaneous immune-related adverse events

Journal for ImmunoTherapy of Cancer
Background Dupilumab has been added to National Cancer Comprehensive Network guidelines as a therapeutic strategy for managing certain cutaneous immune-related adverse events (cirAEs) from immune checkpoint blockade (ICB).
Shadmehr Demehri, Kerry L Reynolds, Yevgeniy R Semenov, Matthew Tran, Nicole R LeBoeuf, Suzanne Xu, Guihong Wan, Bonnie W Leung, Emma Beagles, Sara Khattab, Cameron Moseley, Chuck Lin, Marjan Azin, Ninghui Hao   +13 more
doaj   +1 more source

An Italian multicentre study on adult atopic dermatitis: persistent versus adult-onset disease. [PDF]

, 2017
Atopic dermatitis (AD) is a chronic, recurrent, inflammatory skin disease which predominantly affects children. However, AD may persist until adulthood (persistent AD), or directly start in adults (adult-onset AD).
Balato, Anna, Balato, Nicola, Megna, Matteo, Patruno, Cataldo, Rongioletti, Franco, Schena, Donatella, Stingeni, Luca   +6 more
core   +1 more source

Novel Therapeutics for Chronic Obstructive Pulmonary Disease: From Empirical Bronchodilation to Precision Medicine

Respirology, EarlyView.
ABSTRACT Chronic obstructive pulmonary disease (COPD) remains the third leading cause of death worldwide, and conventional bronchodilator‐based therapies have limited efficacy in preventing exacerbations and disease progression. The 2024–2026 period represents a historic inflection point: three mechanistically distinct agents received Food and Drug ...
Naoya Fujino, Hisatoshi Sugiura
wiley   +1 more source

Reduced epithelial suppressor of cytokine signalling 1 in severe eosinophilic asthma [PDF]

, 2016
Severe asthma represents a major unmet clinical need. Eosinophilic inflammation persists in the airways of many patients with uncontrolled asthma, despite high-dose inhaled corticosteroid therapy. Suppressors of cytokine signalling (SOCS) are a family of
Arron, Joseph R, Bradding, Peter, Butler, Claire A, Choy, David F, Doran, Emma, Heaney, Liam G, Johnston, James A, Kissenpfennig, Adrien, O'Rourke, Declan M, Shikotra, Aarti   +9 more
core   +2 more sources

Integrative Analysis of Plasma Proteome and Genome Reveals Novel Drug Targets for Chronic Rhinosinusitis and Nasal Polyps

World Journal of Otorhinolaryngology - Head and Neck Surgery, EarlyView.
ABSTRACT Background Chronic rhinosinusitis (CRS) and nasal polyps (NP) are chronic inflammatory conditions with unsatisfactory treatment outcomes due to frequent recurrence of refractory disease. Identifying new therapeutic targets is essential. Methods We conducted a proteome‐wide Mendelian randomization (MR) analysis by integrating genome‐wide ...
En Zhou, Shi Luo, Yu Xiao, Bin Liu, Xu‐Ping Xiao   +4 more
wiley   +1 more source

Erythema nodosum followed by eosinophilic pneumonia as an adverse effect of dupilumab treatment in a patient with severe asthma

Respiratory Medicine Case Reports
Dupilumab is a monoclonal antibody that has recently been introduced for the treatment of asthma. It has the potential to significantly alter the progression and severity of T2 -dependent diseases, including severe asthma.
Agnieszka Gawlewicz-Mroczka, Marek Przybyszowski, Grażyna Bochenek, Maria Mroczka, Krzysztof Sładek   +4 more
doaj   +1 more source